Comparing SG&A Expenses: AstraZeneca PLC vs Regeneron Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: AstraZeneca vs. Regeneron

In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry giants is crucial. Over the past decade, AstraZeneca PLC and Regeneron Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses have surged by approximately 35%, peaking in 2022. This reflects their aggressive market expansion and strategic investments. In contrast, Regeneron has seen a fivefold increase in the same period, indicating a robust growth trajectory and increased market penetration.

Key Insights

• AstraZeneca: Despite fluctuations, their SG&A expenses consistently remained higher, highlighting their expansive operational scale.
• Regeneron: The steady rise in expenses underscores their growing influence and strategic positioning in the pharmaceutical sector.

These trends offer a window into the strategic priorities of these companies, providing valuable insights for investors and industry analysts alike.